Can a supplement calm chronic dizziness? new trial aims to find out
NCT ID NCT06741358
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tests whether a supplement called Glialia can help people with persistent postural dizziness (PPPD). The trial will include 20 PPPD patients and 10 healthy controls, all of whom will take either Glialia or a placebo daily for 60 days. Researchers will measure brain inflammation markers and assess balance and quality of life to see if the supplement reduces symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Glialia supplement (palmitoylethanolamide and other ingredients)
- What this could lead to
- If it works, this could point toward a supplement-based treatment for persistent dizziness by reducing brain inflammation.
- What could go wrong
- This is a very small pilot study with only 30 people, so results may not apply to everyone. It is also testing a supplement, not a drug, so benefits may be modest.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERSISTENT POSTURAL PERCEPTUAL DIZZINESS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fondazione Santa Lucia IRCCS
RECRUITINGRome, RM, 00142, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.